anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention discloses Chinese herbal medicine for treating chilblain. The Chinese herbal medicine is composed of nine kinds of Chinese herbal medicine. The Chinese herbal medicine contains 18% of shenghuangqi, 18% of nenguizhi, 18% of quandanggui, 9% of ziyougui, 9% of sheet dried ginger, 9% of stigma croci, 9% of dachuanjiao, 5% of beixixin and 5% of chaonao according to the weight percentage of a drug. After the impurity of the Chinese herbal medicine is removed, the Chinese herbal medicine is dried, then is crushed, is stirred and mixed and then is put in a cylinder jar. The alcohol of which the concentration is 95 % is injected in the cylinder jar in the proportion that 1 kilogram of drugs are added with 4000 ml of alcohol of which the concentration is 95 %. The cylinder jar is sealed and is unsealed after the drug is soaked for eight days. Drug dregs are filtered, and clean physic liquor is obtained and is used for treating the chilblain. The chilblain at every part of a human body is suitably used, with no toxic side effect and allergic reaction. The present invention adapts to the treatment of various non-ulcer type and ulcer type chilblains, particularly the early repair of the ulcer surface of the ulcer type chilblain, has the advantage of conspicuous curative effect and shortens treatment time. The effective rate and the cure rate for the chilblains of various types are both more than 97%.
The present invention relates to a method for preparing detoxifying tablets, which belongs to the technical field of the preparation method of Chinese patent medicine. Infectious diseases are caused by microbial contamination under the condition of immunological function reduction. For many years, Western clinical treatment is only limited to antibiotic treatment, and immunological function enhancement is neglected. Thus, toxic or side effect is great, and a curative effect is not ideal. The present invention has the technical scheme that philippine violet herb, mongolian dandelion herb, wild chrysanthemum, baical skullcap root, golden thread, amur corktree bark, figwort root, ophiopogon root, rehmannia root, peppermint and fineleaf schizonepeta herb are taken to prepare detoxicating Zihuang tablets. The detoxicating Zihuang tablet has the advantages that traditional Chinese medicine is used as antimicrobial medicine by the preparation of the detoxicating Zihuang tablets, infectious disease treatment is fundamentally improved, and the preparation of the detoxicating Zihuang tablets is evolution and innovation for treating infectious diseases. The detoxicating Zihuang tablet is effective medicine which is clinically used for treating aphtha, swelling and pain the throat, toothache, the reddish swelling eye, sores, carbuncles, furuncle poison, etc. and has the efficiency of removing toxin for detumescence, clearing heat and nourishing yin.
Dietary advice and iron therapy are considered the cornerstones of treating a patient with non-severe IDA. The foods that are rich in Iron include meat and poultry products, egg, green leafy vegetables, jaggery, dry fruits etc. Iron in food is of two types viz. haem iron and non haem iron. Haem Iron has excellent bioavailability but the bioavailability of the non-haem Iron in the food stuffs is considerably affected by the presence of substances like phosphates, phytates, tannins and fibres. On the other hand, Ascorbic acid, sugars and other acidic substances in the food enhance the iron absorption. The bulk of food consumed by a child is too less to provide him with therapeutic amounts of iron form diet alone. In the developing countries, the child is quite unlikely to get poultry products and meat as a source of haem Iron. If in this situation, the child is provided with food cooked in Iron utensil, then it provides additional Iron to meet the increased demand. This will not only be cost effective but it will also alter the cooking practices and thereby have a long term effect on the iron status of the entire family. Thus it will treat the IDA in the index case and will also benefit other family members who may be having borderline or overt iron deficiency. This cost effective measure if incorporated in the health policy of the country will certainly have widespread positive implications on the health of the general population.
The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
Intracerebral hemorrhage (ICH) is a hemorrhagic disease with high mortality and disability rates. Curcumin is a promising drug for ICH treatment due to its multiple biological activities, but its application is limited by its poor watersolubility and instability. Herein, platelet membrane-coated curcumin polylactic-co-glycolic acid (PLGA) nanoparticles (PCNPs) are prepared to achieve significantly improved solubility, stability, and sustained release of curcumin. Fourier transform infrared spectra and X-ray diffraction assays indicate good encapsulation of curcumin within nanoparticles. Moreover, it is revealed for the first time that curcumin-loaded nanoparticles can not only suppress hemin-induced astrocyte proliferation but also induce astrocytes into neuron-like cells in vitro. PCNPs are used to treat rat ICH by tail vein injection, using in situ administration as control. The results show that PCNPs are more effective than curcumin-PLGA nanoparticles in concentrating on hemorrhagic lesions, inhibiting inflammation, suppressing astrogliosis, promoting neurogenesis, and improving motor functions. The treatment efficacy of intravenously administered PCNPs is comparable to that of in situ administration, indicating a good targeting effect of PCNPs on the hemorrhage site. This study provides a potent treatment for hemorrhagic injuries and a promising solution for efficient delivery of water-insoluble drugs using composite materials of macromolecules and cell membranes.
Myalgia is a common symptom of Leptospira infection in humans. Autopsies have reported that muscle tissue shows degeneration and necrosis of the myofibers and infiltration of inflammatory cells composed mainly of macrophages and lymphocytes. It remains unclear whether Leptospira directly infects the muscle and how the infiltrating inflammatory cells are involved in muscle fiber destruction. This study evaluated the relationship between histopathological changes and leptospiral localization in the muscle tissue of a hamster model. The influence of macrophages in skeletal muscle injury was also investigated, using selective depletion of macrophages by administration of liposomal clodronate. Hamsters infected subcutaneously with Leptospira interrogans serovar Manilae strain UP-MMC-SM showed myositis of the thighs adjacent to the inoculated area beginning at 6 days post-infection. The myositis was non-purulent and showed sporadic degeneration and necrosis of muscle fibers. The degeneration of myofibers was accompanied by aggregations of macrophages. Immunofluorescence staining revealed leptospires surrounding the damaged muscle fibers. Subcutaneous injection of formalin-killed Leptospira or intraperitoneal injection of live Leptospira caused no myositis in hamster thighs. Liposomal clodronate treatment in infected hamsters reduced macrophage infiltration in muscle tissue without impacting bacterial clearance. Muscle necrosis was still observed in the infected hamsters treated with liposomal clodronate, and there was no significant change in serum creatine kinase levels compared to those in animals treated with liposomes alone. Our findings suggest that leptospiral invasion of muscle tissue from an inoculation site leads to the destruction of muscle fibers and causes non-purulent myositis, whereas the infiltrating macrophages contribute less to muscle destruction.
The invention belongs to the field of medicinal preparations, and provides octreotide acetate injection and a preparation process thereof. The octreotide acetate injection of the invention comprises 5.0g of octreotide acetate, 169.3g of lactic acid, 2200.0-2300.0g of mannitol, a proper amount of sodium bicarbonate and the balance of water for injection per 5 ten thousand mL of injection, wherein the pH value of the octreotide acetate injection is 4.0-4.2. The preparation process is carried out under the aseptic condition, the pH value of the solution and the temperature of the solution are controlled, and a special batching system, magnetic stirring and two-stage sterilization and filtration steps are adopted. The prepared injection can be stored at room temperature for 6 months, can be stored in a refrigerated manner for 4 years, has good safety, and is convenient for product transportation and distribution. The method has the advantages of mature process, controllable quality, low energy consumption, economy and practicability. The invention provides safe, effective and high-quality octreotide acetate injection for clinic.
The molecular mechanisms of peroxisome biogenesis have begun to emerge: in contrast, relatively little is known about how the organelle functions as cells age. The present inventors characterized age-related changes in peroxisomes of human cells and showed that aging compromises peroxisomal targeting signal 1 (PTS1) protein import, with the critical antioxidant enzyme, catalase, especially affected. The number and appearance of peroxisomes are altered in these cells, and the organelles accumulate the PTS1-import receptor. Pex5p, on their membranes. Concomitantly, cells produce increasing amounts of the toxic metabolite, H 2 O 2 , and this increased load of reactive oxygen species (ROS) may further reduce peroxisomal protein import and exacerbate the effects of aging. Disclosed are novel compositions and methods for restoring catalase in peroxisomes by use of targeted catalase modified at its C-terminus and/or N-terminus, optionally in combination with polypeptides which promote cellular uptake of proteins, to prevent or overcome the changes that follows aging or that are associated with a number of diseases or disorders.
PROBLEM TO BE SOLVED: To obtain a cosmetic having more improved beautifully whitening effect even though using a conventional beautifully whitening agent by including a shielding powder and a beautifully whitening agent. SOLUTION: This cosmetic contains (A) a shielding powder, e.g. a powder containing >=50 wt.% of a doping type titanium dioxide or zinc oxide and (B) a beautifully whitening agent, e.g. ascorbic acid, a glycoside of hydroquinone, a 6-12C aromatic compound having a phenolic hydroxyl group, (e.g. caffeic acid or syringic acid), tranexamic acid. In the cosmetic, the component A is preferably contained in a content of 1-20 wt.% when it is a fundamental cosmetic, 1-20 wt.% when a make up cosmetic of an emulsifier type and 1-50 wt.% when a non-emulsifier type make up cosmetic and the component B is preferably contained in a content of 0.01-10 pts.wt.
The intervention will consist in gathering patient-reported experiences and outcomes of the safety of the healthcare patients received in their PC centres during the previous 12 months. This information will be processed and fed back to their healthcare professionals to help them identify potential safety problems, and then target improvements based on problematic areas.
Participants in this group will be enrolled in Benin and will receive nutritional support from the hospital where they receive care. They will be followed for 12 months.
A weight control product, preferably in the form of a tablet or capsule, comprises a mixture of guggul extract and at least one phosphate salt selected from calcium phosphate, sodium phosphate, or potassium phosphate. The guggul extract is preferably an ethyl acetate extract of the resin obtained from the plant Commiphora mukul or Commiphora wightii and may contain between 5 to 50 % guggulsterones. The phosphate salts may be monobasic or dibasic. The product may also contain one or more additional components such as phosphatidyl choline, L-tyrosine or hydroxy citric acid (HCA). The product was effective in reducing body weight and percent body fat in human subjects. It was also found to reduce blood plasma lipid levels and cholesterol levels in hypolipidaemic humans. A improvement in mood states of the subjects was also reported. A synergistic effect of the mixture is reported over the effect of guggul extract alone or the phosphate salt(s) alone.
Patients receive oral temozolomide once daily on days 1-42 and oral thalidomide once daily on days 1-56. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 2 additional courses of therapy beyond CR.
Technique of breathing exercises: Regular aerobic exercises in a form breathing exercises included duration of 30 min. at 40-70% VO2 max. performed 2-3 per week. Each woman practiced deep breathing exercises 30 min. in the of form (diaphragmatic breathing exercises, 15 min. and lateral costal breathing exercises 15 min.) 3 times per week for 12 weeks.
A method of diagnosing cancer includes the steps of, in a sample obtained from a subject, determining the level or activity of HDAC2. A reduced level or activity of HDAC2 is indicative of cancer. HDAC2 protein expression is preferably determined. Indirect determination of HDAC2 expression is also possible, preferably by looking at the expression of genes selected from NCOA4, CTSB, TBCD, PPP2R4 and CORO1C. Methods for predicting the probability of successful treatment of cancer using a hydroxamic acid based HDAC inhibitor and for selecting suitable cancer treatment regimens can also be based upon determining the level or activity of HDAC2. Methods of treatment of cancer may be based upon use of carboxylic acid based HDAC inhibitors or by reconstituting HDAC2 activity.
The present invention relates to a toothpaste composition comprising: a liquid composition containing gold nanoparticles having zero valence electrons (see FIG. 1); and a periodontal disease symptom relief active ingredient. The liquid composition has gold nanoparticles which are dispersed at a concentration of 1 to 5000 ppm. The gold nanoparticles have a shape of at least one among a plate flake, a sphere, and a polyhedron, and have a long side of 0.5 to 100 nm. It is possible to improve the effect of skin or body penetration of symptom-relieving active ingredients for periodontal diseases (soreness of teeth, bleeding gums, or pain in gums, etc.) included with the gold nanoparticles. Thus, it is possible to maximize a symptom relief effect.
This document describes a search engine that accepts as input different types of data files and conditions for search parameters, including both single and multiple time points, concatenates these data, and outputs data from the different types of files that satisfies the specified search conditions. In one aspect, a method includes receiving a selection of a multiple input data files that each include data on which a search is to be performed. The input data files include different types of data files having different data formats. An in-memory data structure that includes the data of the input data files arranged in a common format is generated. For each of one or more search parameters, data indicating a condition for the search parameter is received. A set of data that satisfies the condition of each of the one or more search parameters is identified in the in-memory data structure.
The invention relates to an antigenic epitope of spring viraemia of carp and belongs to the technical field of biology. According to the invention, by virtue of phage display technique, a positive clone is screened out by the use of spring viraemia of carp virus (SVCV) monoclonal antibody, a conserved sequence binding to the SVCV monoclonal antibody is found out, a clinical diagnosis reagent is prepared by the screened antigenic epitope, and spring viraemia of carp is prevented and treated by a small molecular antigen peptide as a vaccine. The gene sequence of the invention is SEQ ID NO:1. The phage display technique is utilized to screen the positive clone by SVCV monoclonal antibody and find out the conserved sequence which can bind to the monoclonal antibody with the ability of SVCV activity neutralization in a random peptide library. The site of the antigenic determinant is determined, and the relationship of its sequence, structure and function is analyzed. The study of inhibition effect to SVCV generated from the competitive binding of small peptide to SVCV receptor will have a huge application value for taking small molecular antigen peptide as vaccine in the future.
Following tetraplegia, independence for completing essential daily tasks, such as opening doors and eating, significantly declines. Assistive robotic manipulators (ARMs) could restore independence, but typically input devices for these manipulators require functional use of the hands. We created and validated a hands-free multimodal input system for controlling an ARM in virtual reality using combinations of a gyroscope, eye-tracking, and heterologous surface electromyography (sEMG). These input modalities are mapped to ARM functions based on the user's preferences and to maximize the utility of their residual volitional capabilities following tetraplegia. The two participants in this study with tetraplegia preferred to use the control mapping with sEMG button functions and disliked winking commands. Non-disabled participants were more varied in their preferences and performance, further suggesting that customizability is an advantageous component of the control system. Replacing buttons from a traditional handheld controller with sEMG did not substantively reduce performance. The system provided adequate control to all participants to complete functional tasks in virtual reality such as opening door handles, turning stove dials, eating, and drinking, all of which enable independence and improved quality of life for these individuals.
The present invention provides a monoclonal antibody which specifically forms a complex with TGF alpha  in formalin-fixed, paraffin-embedded tissue sections which has an affinity of a least 107, and which is directed to the epitope to which monoclonal antibody 213-4.4 (ATCC No. HB9992) is directed. The invention further provides the above-described monoclonal antibody wherein the epitope consists essentially of amino acids 34-43 of TGF alpha . Additionally, the invention concerns the monoclonal antibody 213-4.4 (ATCC No. HB9992). The invention also provides a method of detecting TGF alpha  in tissue sections of a tissue in which normal tissue is characterized by the absence of TGF alpha  and neoplastic tissue is characterized by the presence of TGF alpha  in a subset of such neoplastic tissue which comprises contacting the tissue sections with an antibody directed to an epitope on TGF alpha  under conditions such that the antibody binds to the tissue sections detecting the antibody bound to the tissue sections and thereby detecting TGF alpha in the tissue sections. The invention further provides the monoclonal antibody 134A-2B3 (ATCC No. HB9993). Additionally, the invention concerns the monoclonal antibody 137-178 (ATCC No. HB9994).
Phase B: If tolerated study medication during Phase A (i.e., the closed label, double-blind phase of the trial) then enter a six-week, open-label phase. Participants judged as responders during Phase A continue the same dose of study medication. Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
The present invention relates to viruses containing glycoproteins with furin binding sites. For BRSV it has been found that the 27AA IFCSP is not essential for cell fusion activity of the F protein and the deletion or replacement of at least part of the IFCSP does not destroy F function for productive BRSV replication. Removal of Gly110 to Arg 136 and transient expression of the resulting protein (Fins) resulted in formation of syncitia which were slightly smaller that those induced by wt F. thus, it has been found that oligopeptides, or bioactive proteins, can be integrated between 2 furin cleavage sites of a carrier glycoprotein, such as the furin cleavage sites of an F protein of an RSV. Due to the processing of the precursor protein, resulting in the cleavage at the furin cleavage sites, the heterologous sequence may be excised and consequently be secreted by a virus-infected cell. This concept can be applied likewise to other glycoproteins containing two furin cleavage sites, where the original sequence between the cleavage sites may replaced (in part) by a heterologous sequence or may simply be deleted. In proteins with one furin cleavage site, heterologous sequences may be inserted together with the sequence for a second cleavage site, thus creating a situation where the heterologous sequence is again flanked by two furin cleavage sites in the recombinant protein. Processing of the mutated protein will than also result in the excision of the heterologous sequence which may be secreted by virus infected cells. Viruses wherein glycoproteins are modified in one of the above-described ways, can be used for, for example vaccine purposes.
Given that current androgenetic alopecia (AGA) medications have adverse effects such as sexual dysfunction and drug dependence, researchers are actively exploring natural bioactive ingredients and innovative approaches (e.g., transdermal drug delivery systems) to effectively combat hair loss with minimal side effects. Herein, we develop a new transdermal drug delivery system incorporating globefish skin collagen peptides with dissolving microneedles (GSCPs-MNs) for hair regrowth. These microneedles generate skin micro-wounds upon application, which not only improves the efficiency of bioactive ingredients delivery, but also stimulates signals involved in hair follicle (HF) regeneration. Our in vivo study shows that minimally invasive implanted GSCPs-MNs are more effective than topical GSCPs in reducing inflammation and promoting collagen formation. Additionally, the upregulation of vascular markers including VEGF and CD31 alongside the downregulation of TNF-α, IL-1β, and malondialdehyde (MDA) index indicate that GSCPs-MNs can significantly alleviate inflammation and oxidation, as well as promoting vascularization and HF functionalization. Overall, our findings suggest that GSCPs-MNs can effectively promote hair regrowth in AGA mice, which offer excellent prospects for the development of new therapeutics and cosmetic supplements for hair loss, along with the combined drug delivery optimization, which could alleviate hair loss in patients with AGA.
In addition to SmartQuit (the app), study participants will receive the content in the form on one growth mindset tip (sent in an email) per day starting on the first day of the study. Email exercises will be sent out every 3 days and there are a total of 8 emails.